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Abstract Introduction: Lung cancer is the most commonly diagnosed cancer worldwide and
causes approximately 1–2 million deaths per year. Non-small cell lung cancer (NSCLC) accounts
for at least 80% of all lung cancer cases, presenting as locally advanced disease in approximately
25–30% of cases and as metastatic disease in approximately 40–50% of cases.
Aim of the work: To compare symptom control in patients with inoperable, locally advanced or
metastatic NSCLC using two different regimens of palliative external beam radiotherapy (RT), and
to determine toxicity profile, health related quality of life (HRQOL), tumor control, and overall
survival.
Patients and methods: A prospective clinical study included 30 patients who were randomly
assigned into two groups; group (A) 15 patients received RT regimen of 10 fractions of 3 Gy over
2 weeks to a total dose of 30 Gy, and group (B) 15 patients received RT regimen of two fractions of
8.5 Gy days 1 and 8 to a total dose of 17 Gy. All patients in the study were subjected to the follow-
ing; pretreatment evaluation, RT, patient’s assessment, HRQOL, tumor control, and overall sur-
vival.
Results: The hypo fractionated RT regimens used in this study proved to be equally effective as
the more protracted regimen in terms of palliation of the intrathoracic symptoms, treatment toler-
ance, HRQOL, and overall survival. This may hopefully convince at least some radiation oncolo-
gists still using more protracted regimens to adopt this simple and efficient treatment.
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Conclusion: Palliative RT plays an important role of palliation of symptomatic intra thoracic dis-
ease and in preservation of HRQOL in patients who have limited expected survival time and or
intolerance to combined chemotherapy and radical RT regimens.
 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.
Introduction 6. Unfit for chemotherapy.
7. Patients with relapse in the chest after previous surgery.
8. Previous chemotherapy, but no earlier RT to the pri-
mary tumor.
9. No Prior invasive malignancy (except non-melanoma-
tous skin cancer).
10. Signed study specific informed consent prior to study
entry.
Methods
All patients in the study were subjected to the following:
Pretreatment evaluation
1. History taking and physical examination.
2. Current weight, height, and detection of the weight loss in
the past six months.
3. Assessment of ECOG performance status [6].
4. Biopsy was performed by fiber optic bronchoscopy (FOB)
or CT guided biopsy.
5. Staging workup including X-ray chest, CT chest, abdomen
and pelvis.
6. Cerebral CT or MRI and bone scans were only performed
when indicated.
7. Determination of tumor measurements.
8. Routine laboratory studies.
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Open access under CC BY-NC-ND license.Lung cancer is the most commonly diagnosed worldwide, and
causes more deaths than any other cancer. In the year 2008,
approximately 15% of new lung cancer in the United States
will be diagnosed, with an estimated death rate of 31% in
males and 26% in females [1]. In Egypt, however there is no
population based cancer registry, but based on Gharbia cancer
registry, lung cancer represents 5.1% of all incident cancers [2].
The treatment of NSCLC which represents 80% of all lung
cancers is still a challenge for oncologists. In the past decade,
combined-modalities treatment in stage III disease and chemo-
therapy for stage IV disease improved the survival and
HRQOL. But unfortunately many patients are unfit to under-
go these intensive treatments [3,4].
Consequently, a shorter course of hypo fractionated RT for
palliation, if effective and unduly toxic, would be an attractive
alternative to more protracted regimens, so clinical trial that is
organized to ensure homogeneity in both patient characteris-
tics and treatment interventions is needed. Shorter hypofrac-
tionated schedules require fewer trips to the RT facility for
the patient, and in all likelihood, smaller directly and indirectly
costs for society, especially for developing countries (like
Egypt) with limited resources [4].
To measure the effect of palliative intervention, it is recom-
mended to use patients’ self-reported assessment using
validated instruments but unfortunately, most reports regard-
ing palliative fractionation in NSCLC have used clinical
assessment of palliative effect only [5].Aim of the work
Primary objective was to compare symptoms’ control in
patients with inoperable, locally advanced or metastatic
NSCLC using two different regimens of palliative RT.
Secondary objective was to determine; toxicity profile,
HRQOL, tumor control, and overall survival.
Patients
This was a prospective clinical study that included 30 patients,
who were randomly assigned into one of two groups:
Group A: Consisted of 15 patients who received RT regimen
of 10 fractions of 3 Gy over 2 weeks to a total dose of 30 Gy.
Group B: Consisted of 15 patients who received RT regimen
of two fractions of 8.5 Gy days 1 and 8 to a total dose of 17 Gy.
Conditions for Patient Eligibility:
1. Cytological proven diagnosis of NSCLC.
2. Inoperable Stage III or IV disease.
3. AgeP 18 years.
4. Eastern Cooperative Oncology Group (ECOG) Perfor-
mance Status (PS)P 2 (Appendix I). [6]
5. Pulmonary symptoms attributable to the primary tumor.
9. The patients were categorized according to the American
Joint Committee on Cancer (AJCC) staging system [7].
Updated after the of the end of patients accrual.
Radiation therapy
RT was given with Mega-voltage linear accelerator with pho-
ton beams of P6 MV.
Immobilization, simulation, and localization
 Patient setup was achieved by the use of customized immo-
bilization devices.
 The patient position was supine with the arms above the
head.
 A treatment planning CT scan for defining target volumes.
 Contrast use improved the contouring of centrally located
tumors.
 The treatment isocenter was located in the tumor mass.
Treatment planning/target volumes
1. Gross Tumor Volume (GTV): included the gross primary
tumor and the adjacent pathologically enlarged lymph nodes.
2. Planning Target Volume (PTV): represents an additional
margin around GTV to compensate for the variability of
treatment set up. A margin of 1.5–2 cm around the GTV
was required in all directions to define the PTV.
Dose specifications
A total dose of 30 Gy (3 Gy/fraction) over 2 weeks in group A
and 17 Gy (8.5 Gy/fraction) in group B was prescribed.
Co-medication
To prevent possible side effects from larger fractions, patients
in group II were prophylactically administered (prednisolone,
analgesics bronchodilators and oxygen).
Patient assessment
Symptom control
Patients’ self-reported symptoms control. European Organiza-
tion for Research and Treatment of Cancer (EORTC) lung
cancer-specific module QLQ-LC13 (Arabic version) was used
(Appendix I) [8]. The QLQ-LC13 module contains items for
measuring dyspnea, cough, hemoptysis, mucositis, dysphagia,
peripheral neuropathy, alopecia, pain, and analgesic consump-
tion or effect. Mean scores for cough, hemoptysis, dyspnea,
and chest pain were taken at base line, 1, 6 and 16 weeks after
the end of RT. All these symptoms were linearly transformed
to a scale from 0 to 100, with a higher score on the scale indi-
cating a high degree of symptoms.
Clinicians’ assessed symptoms control. Symptoms such as
cough, hemoptysis, dyspnea, and dysphagia and chest pain
were categorized according to the Common Terminology Cri-
teria for Adverse Events (CTCAE) version 3.0 (Appendix III)
[9] and recorded at baseline and at 1 week, 6 weeks, and
16 weeks after completing RT.
Toxicity profile
Patients’ self-reported toxicity. This study used both the
EORTC Quality of Life Questionnaire (QLQ)-C30 and the
EORTC lung cancer-specific module QLQ-LC13 (Arabic ver-
sions) [8].
Clinicians’ assessed toxicity. This study utilized the criteria of
the CTCAE version 3.0 for grading of all adverse events [9]. It
was assessed at the follow-up times.
Health related quality-of-life
This study used the EORTC Quality of Life Questionnaire
(QLQ)-C30 [8].
Tumor control
Chest radiographs or CT chest scans to assess the tumor re-
sponse within the RT fields were obtained at 6 weeks and/or
4 months after RT. These were categorized into five radio-
graphic responses: complete response, partial response (tumor
regression P50%), minor response (tumor regression P25%
but <50%), stable disease (no change in lesion size
or < 25% increase or decrease), and progressive disease
(growth in irradiated volume of P25%) [4].
Overall survival
Was calculated from the date of study entry till the date of
death, or lost follow up. It was estimated by Kaplan–Meier’s
method [10].
Statistical analysis of the data
Data were analyzed using SPSS software package version 18.0
(SPSS, Chicago, IL, USA). Quantitative data were expressed
using Range, mean and standard deviation while Qualitative
data were expressed in frequency and percent. Qualitative data
were analyzed using Chi-square test also exact tests such as
Fisher exact and Monte Carlo were applied to compare the
two groups while, McNemar-Bowker was used to analyze
the significance between the different stages. Quantitative data
were analyzed using Mann Whitney test to compare between
two groups. Wilcoxon Signed Rank test was used to compare
between the different periods.
Results
Clinico pathological features
1. Age: In the whole series the age ranged between 30 and
80 years, with a mean age of 60.93 and 59.33 years for
group A and group B, respectively.
2. Gender: Where 80% of the patients in group A were males
and 93.3% of the patients in group B were males with no
significant statistical difference.
3. Smoking history and frequency: The majority of patients in
both groups were smokers; where 80% of patients in group
A and 86.7% of patients in group B were smokers with no
significant statistical difference.
4. Performance status (P.S): According to the ECOG scale the
P.S of the majority of patients in both groups were 3
(73.3% and 53.3% of patients in group A and B, respec-
tively) whereas 26.7% and 40.0% of patients in group A
and B, respectively were 2 (Fig. 1).
5. Presenting symptoms: According to CTCAE. In group A
the most significant symptoms gradeP2 were cough, dysp-
nea, hemoptysis and chest pain with a frequency of 100%,
100%, 60% and 46.7%, respectively, whereas in group B
the symptoms were also cough, dyspnea, hemoptysis and
chest pain with a frequency of 100%, 93.3%, 66.7% and
66.6%, respectively (Table 1).
6. Tumor characteristics: As shown in Table 2 the majority of
the patients incorporated in this study were of T3 and T4
lesions, as 60% of patients in group A were T3 while
33.3% were T4 and 46.7% of patients in group B were
T3 while 53.3% were T4. Whereas only I patient in this
study was T2 and he was in group A. As regards the nodal
status which was radiologically proved, N2 lesions predom-
inate in both groups and constituted 80% and 73.3% in
group A and B, respectively.
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7. Methods of obtaining biopsy: Most of the patients in both
groups 66.7% were diagnosed through FOB biopsy. While
the remaining 33.3% were diagnosed through CT guided
biopsy.
8. Histopathological type: Squamous cell carcinoma was the
commonest pathological type in both groups and repre-
sented 40% and 46.7% in group A and group B, respec-
tively (Fig. 2).
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Figure 1 Comparison between the two studied groups according to Performance status.
Table 1 Presenting symptoms and weight loss among the
studied groups.
Group A (30 GY) Group B (17 GY) Test of significance
No. % No. %
Dyspnea
GI 0 0.0 1 6.7 MCp= 1.000
GII 5 33.3 6 40.0
GIII 9 60.0 8 53.3
GIV 1 6.7 0 0.0
Hemoptysis
Non 6 40.00 5 33.3 MCp= 0.743
GII 6 40.0 4 26.7
GIII 2 13.3 5 33.3
GIV 1 6.7 1 6.7
Cough
GII 5 33.3 4 26.7 FEp = 1.000
GIII 10 66.7 11 73.3
Chest pain
Non 2 13.3 1 6.7 MCp= 0.774
GI 6 40.0 4 26.7
GII 3 20.0 5 33.3
GIII 4 26.7 5 33.3
Dysphagia
Non 8 53.3 6 40.0 MCp= 0.221
GI 6 40.0 4 26.7
GII 1 6.7 5 33.3
Weight loss
No 3 20.0 4 26.7 FEp = 1.000
Yes 12 80.0 11 73.3
MCp, p value for Monte Carlo test; FEp, p value for Fisher Exact
test.
Table 2 Tumor size, nodal status and TNM staging.
Group A (30 GY)Group B (17 GY)Test of
significance
No. % No. %
Tumor size
T2 1 6.7 0 0.0 MCp= 0.458
T3 9 60.0 7 46.7
T4 5 33.3 8 53.3
Nodal status
N1 1 6.7 1 6.7 MCp= 1.000
N2 12 80.0 11 73.3
N3 2 13.3 3 20.0
Stage
IIIA 2 13.3 2 13.3 MCp= 1.000
IIIB 4 26.7 5 33.3
IV 9 60.0 8 53.3
Brain 1 6.7 1 6.7
Bone 1 6.7 0 0.0
Liver 3 20.0 4 26.4
Multiple site 1 6.7 1 6.7
Suprarenal 3 20.0 2 13.3
MCp, p value for Monte Carlo test.
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9. Previous Chemotherapy: Eleven out of 15 patients in group
A had received chemotherapy before study entry. As
regards group B, 9 out of 15 patients had received previous
doses of chemotherapy. All of the patients in both groups
had received cisplatin based chemotherapy.
Symptoms control
Patients’ self reported symptom control
100% of patients in both groups had reported palliation of
hemoptysis, while dyspnea was improved in 73.3% and 60%
of patients in group A and group B, respectively. Cough was
palliated in 66.7% and 73.3% of patients in group A and
group B, respectively. Symptomatic improvement of chest pain
was 66.7% and 72.7% of patients in group A and group B,
respectively (Table 3).
Among both groups the mean scores of dyspnea, cough,
and hemoptysis were improved significantly in the week 1, 6
and 16 following RT, with no statistically significant differ-
ences among the 2 groups; while the mean score of chest pain
was improved significantly only in week 1 and 6 and worsened
again in week 16, with no statistically significant differences
between the 2 groups (Fig. 3).
Clinicians’ reported symptom control
Hemoptysis had the highest improvement rate 100% in both
groups which is noted at the first week after RT and seemed
to last throughout the planned follow up period. Dyspnea
was palliated in 10 (66.7%) out of 15 patients with significant
Table 3 Numbers of patients reporting symptomatic improvement after RT.
Start After 1 week After 6 weeks After 16 weeks Overall improvement
No. % No. %
Dyspnea A 15 /15 100.0 10/15 1/5 0/2 11/15 73.3
B 15/15 100.0 8/15 1/7 0/4 9/15 60.0
FEp 0.700
Hymoptysis A 9/15 60.0 9/9 – – 9/9 100.0
B 10/15 66.7 10/10 – – 10/10 100.0
FEp –
Cough A 15/15 100.0 9/15 1/6 0/3 10/15 66.7
B 15/15 100.0 11/15 0/4 0/2 11/15 73.3
FEp 1.000
Chest pain A 9/15 53.3 6/9 0/3 0/0 6/9 66.7
B 11/15 73.3 7/11 1/4 0/1 8/11 72.7
FEp 1.000
FEp, p value for Fisher Exact test.
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Figure 2 Comparison between the two studied groups according to Histopathology.
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dyspnea in group A. Specifically, dyspnea improved in 9 pa-
tients at the first week after RT and in I patient at the sixth
week; while 9 (64.3%) out of 14 patients with significant dysp-
nea in group B were palliated, 6 of them at the first week after
RT and 3 at the sixth week. Cough was improved in 9 (60%)
out of 15 patients with significant cough in group A, 8 of them
were improved at first week after RT and only I patient at the
sixth week; while 10 (66.7%) out of 15 patients with significant
cough in group B were palliated, all of them at the first week
after RT. As regards patients with significant chest pain, in
group A 5 (71.4%) out of 7 patients were palliated, all at the
first week after RT; while in group B 7 (70%) out of 10 patients
with significant chest pain were improved, all of them at the
first week after RT (Table 4).
Toxicity
Patients’ self-reported toxicity
Dysphasia is considered the main side effect of RT treatment
as recorded by patients. The mean scores of dysphasia were
significantly increased in both groups as reported at the first
week after RT with no significant difference between both
groups, followed by improvement as reported at the later ques-
tionnaires. Patients in group A reported increased emesis in the
questionnaires collected at the first week after RT.
Clinicians’ reported toxicity
Nine patients in group A suffered from significant dysphagia
as assessed in the first week after RT, 8 of them were grade
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Figure 3 Comparison between the two studied groups according to patients’ self reported symptom control.
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II and only 1 patient suffered from grade III dysphagia, while
in group B 7 patients suffered from significant dysphagia, 7 pa-
tients were grade II, while 2 patients were grade III. No spinal
toxicities were detected in any of the patients of both groups.
Skin toxicity was detected only in 1 patient in group A in
the form of Grade I erythema which was transient and im-
proved without treatment, skin toxicities of higher grades were
not seen. Clinically vomiting after RT was transient and of
grade I and relieved by the routine medications.
Health related quality-of-life
There were no statistically significant differences in the mean
scores of all items between the two groups at base line and dur-
ing follow up times. Except for increased emesis in the first
week reported by patients in group A and decreased constipa-
tion in the sixteenth week reported by patients in group B,
there were no other differences as regards the whole question-
naire items at the follow up times.
Tumor control
Chest X-rays and/or CT chest scans obtained at 6 weeks and/
or 4 months after RT for 14 patients in group A and 14 pa-
tients in group B (2 missed patients, I in each group), revealed
no significant differences in the radiological response between
both study arms, with a Complete response(CR) in only 1 pa-
tient (7.1%) in group B, a partial response(PR) in 2 patients
(14.3%) in group A and 2 patients (14.3%) in group B, a minor
response(MR) in 3 patients (21.4%) in group A and in 3 pa-
tients (21.4%) in group B, a stable disease(SD) in 8 patients
(57.1%) in group A and in 7 patients (50%) in group B, and
a progressive disease(PD) in 1 patient (7.1%) in group A and
in 1 patient (7.1%) in group B. The overall response rate
Table 4 Symptoms improvement as reported by physicians’ assessment.
s Start After 1 week After 6 weeks After 16 weeks Overall improvement
No. % No. %
Dyspnea A 15/15 100.0 9/15 1/6 0/2 10/15 66.7
B 14/15 99.3 6/15 3/8 0/3 9/14 64.3
v2 (p) 0.144 (0.705)
Hymoptysis A 9/15 60.0 9/9 – – 9/9 100.0
B 10/15 66.7 10/10 – – 10/10 100.0
v2 (p) –
Cough A 15/15 100.0 8/15 1/15 0/8 9/15 60.0
B 15/15 100.0 10/15 0/15 0/10 10/15 66.7
v2 (p) 0.144 (0.705)
Chest pain A 7/15 46.7 5/7 0/2 0/0 5/7 71.4
B 10/15 66.7 7/10 0/2 0/1 7/10 70
FEp 0.120
v2: Chi square test.
FEp, p value for Fisher Exact test.
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Figure 4 Comparison between the two studied groups according to response.
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was 35.7% and 42.8% in group A and group B, respectively
(Fig. 4).
Overall survival
Overall survival for patients in the study revealed no signifi-
cant survival difference among the two treatment groups
(P = 0.500; Fig. 6). The median survival was 5 and 6 months
in group A and B, respectively (Fig. 5):
Discussion
Although the effect of chemotherapy in advanced NSCLC in
the 1980s was proven superior to the best supportive care with
respect to survival, HRQOL, and symptom relief, and there
has been an expanded use and increasing efficacy of novel
chemotherapy regimens for this disease during recent years
[11]. Still, thoracic RT remains an important treatment modal-
ity for patients with symptoms from intrathoracic disease.
The study population characteristics were homogenous
between the two study groups with no statistically significant
differences. The mean age was 60.93 and 59.33 years for the
group (A) and the group (B). This was close to the mean age
of the patients randomized in the medical research council
(MRC) I study [12] which was 65 years, and that of the Norwe-
gian study [13] which was 68 years.
The majority of patients in both groups were males 80% in
group A and 93.3% in group B. This male predominance is
found in almost all the previously listed studies except in the
American study [14] in which females were 61% of the study
population.
All cases were histopathologically proved to be NSCLC.
Squamous cell carcinoma (SCC) was the most common
pathological subtype in both groups followed by large cell
carcinoma and adenocarcinoma, this is against the interna-
tional incidence in which adenocarcinoma is the most common
histopathological type of NSCLC, and this could be attributed
to the small number of patients in this study which is not rep-
resentative of the real incidence in the community. Moreover,
most of the patients were males who smoke bad quality of cig-
arettes with high tar content. However, this is matching with
the MRC I, the Norwegian, and the Polish [12,13] studies’
population in which SCC was also the predominate subtype.
Most of the patients incorporated in this study were stage
IV disease 60% and 53.3% in group A and group B, respec-
tively, followed by stage IIIB 26.7% and 33.3% in group A
and group B, respectively. Traditionally, stage IIIA disease
should be treated with a curative intent, with concurrent che-
mo radiotherapy followed by either surgery if gets respectable
and/or chemotherapy. In our study, only patients with poor
prognostic factors in stage IIIA who were not considered as
candidates for any curative treatment were eligible, and those
were only 13.3% of patients in both groups.
Eleven out of the 15 patients in group A had received che-
motherapy before study entry as 8 of them were stage IV at
the time of diagnosis but their pulmonary symptoms were
still insignificant, While the 3 other patients (2 were stage
III B and 1 was stage III A) were receiving induction chemo-
therapy and were planned to receive concomitant chemo
radiotherapy but their condition progressed and their
performance status worsened and became eligible to enter
the study. As regards group B, 9 out of the 15 patients had
received previous doses of chemotherapy as 4 of them were
Figure 5 Kaplan–Meier’s estimate of overall survival.
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metastatic before study entry and 5 patients (4 were stage III
B and 1 was stage III A) were receiving induction
chemotherapy. All of the patients in both groups had re-
ceived cisplatin based chemotherapy.
Considering the poor prognosis for the patients in this
study, the primary end point was the relief of symptoms caused
by the intrathoracic disease, which were dyspnea, cough, hem-
optysis, and chest pain, the results of our study showed that
there was a significant palliation of these symptoms following
RT as reported by patients and also as assessed clinically with
no statistically significant difference among both groups. The
modern definition of palliation (as recommended by the
MRC Cancer Trials Office) encompasses symptom improve-
ment (reduction of existing moderate or severe symptoms),
control (no deterioration in mild symptoms) and prevention
(no deterioration in those with no symptoms) [15]. Such a com-
prehensive assessment is particularly important in the setting
of lung cancer, a tumor typically accompanied by multiple
symptoms. The efficacy of palliative RT depends on the type
of predominant symptom. Several studies demonstrated that
the most effectively palliated symptoms include hemoptysis
and chest pain [14]. In some studies, including the present
study, RT also resulted in effective relief of cough and dyspnea
[12,13].
According to the patients’ reported symptom control, hem-
optysis had the highest improvement rate of 100% in both
groups which is noted at the first week after RT and seemed
to last throughout the planned follow up period as noted by
the significant improvement of the mean scores of hemoptysis
throughout the follow up period. Patients reported improve-
ment in chest pain by 71.4% and 70% in group A and B,
respectively but for a shorter period of time as noted by the in-
creased mean scores of chest pain at week 16 after RT. Cough
was improved in 66.7% and 73.3% of patients in group A and
group B, respectively. While, dyspnea was palliated in 73.3%
and 60% of patients in group A and group B, respectively.
The palliation for both dyspnea and cough was of longer dura-
tion than that of chest pain and continued till week 16 after
RT. There was no statistically significant difference in the pal-
liation rate or degree of all symptoms among both groups.
As regards the clinicians’ symptom evaluation only patients
with significant symptoms at baseline were analyzed, the re-
sults coincide with those reported by patients with no major
discrepancy. Again hemoptysis had the highest overall
improvement in 100% of patients in both groups, followed
by chest pain, dyspnea and cough with overall improvement
rates ranging from 60% to 71.4% with no statistically signifi-
cant difference among both study arms.
These results were in agreement with the results of the pro-
spective randomized trials of the MRC I and II, Sundstrøm et
al., and Senkus-Konefka et al. [13,16]. All these studies showed
a significant palliation of the intrathoracic symptoms after the
hypo fractionated regimen of 17 Gy in two fractions, which
was equal to that achieved by more protracted regimens. The
palliation rate of symptoms at these studies was as follows:
hemoptysis had the highest improvement that ranged from
80% to 100%, denoting the very effective hemostatic control
achieved by RT, cough palliation observed in40–83%; dyspnea
in 40–75%; and chest pain in 50–80%.
These results, however, were challenged by a few studies,
which demonstrated better palliation in patients given higher
radiation doses [17,18]. These discrepancies can at least par-
tially be explained by different fractionation schedules, various
end points and differences in evaluation tools used in particu-
lar studies [18]. In particular, many studies emphasized the
importance of relying more on patient self-assessment than
on physicians’ evaluation, as major differences are observed
between results of both these judgments.
Induced esophagitis was the main toxicity of treatment as
reported by patients and as assessed clinically as well, with
no significant difference among both groups. Sixty percent of
patients in both groups suffered from significant dysphasia
as assessed 1 week after RT, I patient (6.7%) in group A and
2 patients (13.3%) suffered from grade III dysphagia that re-
quired tube feeding & IV fluids. The condition then resolved
rapidly and only 20% of patients in group A and 26.7% in
group B had significant dysphagia at week 6 after RT, these
patients were originally suffering from dysphagia before the
start of treatment due to the local compression of the tumor
over the esophagus. Skin toxicity was detected only in I patient
in group A in the form of Grade I erythema which was tran-
sient and improved without treatment, skin toxicities of higher
grades were not seen. Clinically vomiting after RT was tran-
sient and of grade I and relieved by the routine medications.
No cases of any grade of radiation induced myelopathy nor
pneumonitis were detected in any of the patients in both arms
during the follow up times. These results are in accordance
with some previous randomized trials which reported
Figure 6 A case with a very good radiological response after RT.
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dysphagia as the main toxicity of treatment with no differences
among different fractionation schedules used in these trials
[12,16], while other trials reported more dysphagia in the hypo
fractionated arm [19] and two trial reported more dysphagia in
the more protracted regimen [20]. Spinal toxicities were re-
ported in some studies [21] but in rare cases.
HRQOL was preserved equally in the two study arms with
no significant deterioration in any domain of the EORTC
questionnaires at the follow up times. The QOL was not mea-
sured in many previous randomized control trials (RCTs) [16]
while it was an important endpoint in few other trials [19]. The
results of these trials were contradictory with two trials
reported equivalent QOL in patients treated with the hypo
fractionated to those treated with the more protracted
regimens [22] whereas the other two trials concluded that the
higher doses give better QOL [19].
As regards the local radiographic response to RT, the over-
all response rate was not significantly different among both
study arms (35.7% and 42.8% in group A and group B, respec-
tively). This was close to the results of MRC I trial that showed
a complete response in 7% of patients in the hypofrationated
arm and 5% of the multifractionated regimen, and a partial re-
sponse in 22% and 25%, respectively.
The overall survival for patients in the study revealed no
significant survival difference among the two treatment groups
P value = 0.550. The median survival was 5 and 6 months in
group A and B, respectively. This short overall survival is
not surprising given the overall poor PS of the patients, as well
as that more than half of them were metastatic at treatment
and about two thirds had received previous chemotherapy
and progressed on it.
Our survival results are in accordance to that of the
majority of the RCTs which showed no significant differences
between the hypofrationated and higher dose multifractionated
regimens in terms of survival [22]. The major concern related to
the use of hypo fractionated treatment schedules is their
potential inferiority in terms of overall survival as shown in
three RCTs [19]. Some evidence exists that higher RT doses
result in a modest increase in survival, although at the expense
of higher acute toxicity [20]. The effect of RT dose and regimen
on overall survival, if any, was in all instances limited to patients
with good PS and/or relatively non advanced disease, that is,
those most likely to benefit from improved local control [20].
In contrast to these results, the polish study [16] demonstrated
improved survival in the shorter treatment arm. This intriguing
result should, however, be interpreted with caution due to a rel-
atively small number of patients (100 patients) in this polish
study. Although in two other studies a trend toward improved
survival in the lower dose group was observed in a subset
analysis [23]. It seems reassuring that such a short treatment is
at least not inferior in terms of survival, compared to a standard
schedule.
Apart from purely medical factors, such an approach has
obvious logistic and economic benefits, which is of particular
importance in countries with limited health care resources.
Commonly used treatment schedules are still, however, more
often based on tradition than on clinical research results
[18]. The sources of reluctance toward hypo fractionated reg-
imens include the lack of experience with large single frac-
tion, concerns about its acute toxicity and uncertainty
about the appropriate patient selection for hypo fractionated
RT [18].
Conclusion
Palliative RT alone plays an important role in the palliation of
symptomatic intrathoracic disease and in the preservation of
HRQOL, in patients who have limited expected survival time
and/or intolerance to combined chemotherapy and radical
RT regimens.
The short-term hypo fractionated treatment is convenient
for patients with a limited expected survival. Furthermore,
hypo fractionation schedules require fewer trips to the RT
facility for the patient, and in all likelihood, smaller direct
and indirect costs for society, especially in developing coun-
tries with limited resources.
The hypo fractionated RT regimen used in this study
proved to be equally effective as the more protracted regimen
in terms of palliation of the intrathoracic symptoms, treatment
tolerance, HRQOL, and overall survival. This may hopefully
convince at least some radiation oncologists still using
more protracted regimens to adopt this simple and efficient
treatment.
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Appendix A
ECOG PS scale (Appendix I) [6]
This scale is used to measure performance of which the patient
is capable. For example, a patient in the hospital for metabolic
studies may be fully capable of performing normal activities,
but will remain in bed through his or her own choice. Such a
patient should be coded 0, ‘‘normal.”
0 Fully active; no performance restrictions.
1 Strenuous physical activity restricted; fully ambulatory and
able to carry out light work.
2 Capable of all self-care but unable to carry out any work
activities. Up and about >50 Percent of waking hours.
3 Capable of only limited self-care; confined to bed or chair
>50 percent of waking hours.
4 Completely disabled; cannot carry out any self-care; totally
confined to bed or chair.
EORTC Quality of life questionnaire (QLQ)-C30 and the
EORTC lung cancer–specific module QLQ-LC13 (Arabic
versions)(Appendix II) [8]
EORTC QLQ-C30 (version 3)
ﻧﺤﻦﻣﻌﻨﻴﻮﻥﺑﺒﻌﺾﺍﻟﻤﻌﻠﻮﻣﺎﺕﻋﻨﻚﻭﻋﻦﺻﺤﺘﻚﺍﻟﺮﺟﺎﺀﺍﺟﺐﻋﻦﻛﻞﺍﻻﺳﺌﻠﺔﺑﻨﻔﺴﻚ
ﺑﻮﺿﻊﺩﺍﺋﺮﺓﺣﻮﻝﺍﻻﻣﻜﺎﻧﻴﺔﺍﻻﻛﺜﺮﻣﻼﺋﻤﺔﻟﻚﻻﻳﻮﺟﺪﺟﻮﺍﺏ"ﺻﺤﻴﺢ"ﺍﻭ"ﺧﻄﺄ"
ﺍﻟﻤﻌﻠﻮﻣﺎﺕﺍﻟﺘﻰﺗﺪﻟﻰﺑﻬﺎﺳﻮﻑﺗﺒﻘﻰﻓﻰﻛﺎﻣﻞﺍﻟﺴﺮﻳﺔ.
: ﺍﻟﺮﺟﺎﺀﺍﻣﻸﺍﻟﺤﺮﻭﻑﺍﻻﻭﻟﻰﻻﺳﻤﻚ
: ﺗﺎﺭﻳﺦﻣﻴﻼﺩﻙ)ﺍﻟﻴﻮﻡ،ﺍﻟﺸﻬﺮ،ﺍﻟﺴﻨﻪ )
: ﺍﻟﺘﺎﺭﻳﺦﺍﻟﻴﻮﻡ)ﺍﻟﻴﻮﻡ،ﺍﻟﺸﻬﺮ،ﺍﻟﺴﻨﻪ ):
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ﺎﻗﻼﻃﺍ ﻼﻴﻠﻗ ﺔﻳﺎﻔﻜﻟﺍﻪﻴﻓﺎﻤﺑ ﺍﺪﺟﺮﻴﺜﻛ
؟ﺔﺒﻴﻘﺣﻭﺍﻞﻴﻘﺛﺕﺎﻳﺮﺘﺸﻣﺲﻴﻛﻞﻤﺤﻛﻕﺎﺷﻰﻧﺎﻤﺴﺟﺪﻬﺟﻝﺬﺑﻰﻓﺔﺑﻮﻌﺻﻚﻳﺪﻟﻞﻫ 1 2 3 4
؟ﺔﻠﻳﻮﻃﺔﻓﺎﺴﻣﺮﻴﺳﻰﻓﺔﻠﻜﺸﻣﻚﻳﺪﻟﻞﻫ 1 2 3 4
؟ﺖﻴﺒﻟﺍﺝﺭﺎﺧﺓﺮﻴﺼﻗﺕﺎﻓﺎﺴﻤﻟﺮﻴﺴﻟﺍﻰﻓﺔﻠﻜﺸﻣﻚﻳﺪﻟﻞﻫ 1 2 3 4
؟ﻡﻮﻴﻟﺍﻝﻼﺧﺪﻌﻘﻤﻟﺍﻭﺍﺮﻳﺮﺴﻟﺍﻰﻓﺀﺎﻘﺒﻠﻟﺝﺎﺘﺤﺗﻞﻫ 1 2 3 4
؟ﺽﺎﺣﺮﻤﻟﺍﻝﺎﺴﺘﻏﻻﺍﺲﺑﻼﻤﻟﺍﺀﺍﺪﺗﺭﺍﻞﻛﻻﺍﻰﻓﺓﺪﻋﺎﺴﻤﻟﺝﺎﺘﺤﺗﻞﻫ 1 2 3 4
ﻰﺿﺎﻤﻟﺍﻉﻮﺒﺳﻻﺍﻝﻼﺧ ﺎﻗﻼﻃﺍ ﻼﻴﻠﻗ ﺔﻳﺎﻔﻜﻟﺍﻪﻴﻓﺎﻤﺑ ﺍﺪﺟﺮﻴﺜﻛ
ﻯﺮﺧﺍﺔﻴﻣﻮﻳﺕﺎﻴﻟﺎﻌﻓﻭﺍﻚﻠﻤﻌﺑﻡﺎﻴﻘﻟﺎﺑﺍﺩﻭﺪﺤﻣﺖﻨﻛﻞﻫ 1 2 3 4
ﻍﺍﺮﻔﻟﺍﺕﺎﻗﻭﺍﻰﻓﺕﺎﻴﻟﺎﻌﻓﻭﺍﻚﺗﺎﻳﺍﻮﻫﺔﺳﺭﺎﻤﻣﻰﻓﺍﺩﻭﺪﺤﻣﺖﻨﻛﻞﻫ 1 2 3 4
ﻚﺳﺎﻔﻧﺍﺖﻗﺎﺿﻞﻫ 1 2 3 4
ﻢﻟﺍﻚﻳﺪﻟﻥﺎﻛﻞﻫ 1 2 3 4
ﺢﻳﺮﺘﺴﺗﻥﻻﺔﺟﺎﺤﺑﺖﻨﻛﻞﻫ 1 2 3 4
ﻡﻮﻨﻟﺎﺑﻞﻛﺎﺸﻣﻦﻣﺖﻴﻧﺎﻋﻞﻫ 1 2 3 4
ﻦﻫﻮﻟﺎﺑﺕﺮﻌﺷﻞﻫ 1 2 3 4
ﻚﺘﻴﻬﺷﺕﺪﻘﻓﻞﻫ 1 2 3 4
ﻥﺎﻴﺜﻐﻟﺎﺑﺕﺮﻌﺷﻞﻫ 1 2 3 4
ﺕﺄﻴﻘﺗﻞﻫ 1 2 3 4
ﻙﺎﺴﻣﺍﻦﻣﺖﻴﻧﺎﻋﻞﻫ 1 2 3 4
ﻝﺎﻬﺳﺍﻚﻳﺪﻟﻥﺎﻛﻞﻫ 1 2 3 4
ﺎﻧﺎﺒﻌﺗﺖﻨﻛﻞﻫ 1 2 3 4
ﺔﻴﻣﻮﻴﻟﺍﻚﺗﺎﻴﻟﺎﻌﻓﺵﻮﺷﻊﺟﻮﻟﺍﻞﻫ 1 2 3 4
ﻥﻮﻳﺰﻔﻠﺘﻟﺍﺓﺪﻫﺎﺸﻣﻭﺍﺓﺪﻳﺮﺟﺓﺀﺍﺮﻗﻞﺜﻣﺭﻮﻣﻻﺍﻰﻓﺰﻴﻛﺮﺘﻟﺎﺑﺔﺑﻮﻌﺻﻚﻳﺪﻟﻥﺎﻛﻞﻫ 1 2 3 4
ﺮﺗﻮﺘﻟﺎﺑﺕﺮﻌﺷﻞﻫ 1 2 3 4
ﻖﻠﻘﻟﺎﺑﺕﺮﻌﺷﻞﻫ 1 2 3 4
ﻥﺎﺠﻴﻬﻟﺎﺑﺕﺮﻌﺷﻞﻫ 1 2 3 4
ﺏﺎﺌﺘﻛﻻﺎﺑﺕﺮﻌﺷﻞﻫ 1 2 3 4
ﺀﺎﻴﺷﺃﺮﻛﺬﺘﺑﺔﺑﻮﻌﺻﻚﻳﺪﻟﺖﻧﺎﻛﻞﻫ 1 2 3 4
؟ﺔﻴﻠﺋﺎﻌﻟﺍﻚﺗﺎﻴﺤﺑﻞﺧﺪﺗﻰﺒﻄﻟﺍﻚﺟﻼﻋﻭﺍﺔﻴﻧﺎﻤﺴﺠﻟﺍﻚﺘﻟﺎﺣﻞﻫ 1 2 3 4
؟ﺔﻴﻋﺎﻤﺘﺟﻻﺍﻚﺗﺎﻴﺤﺑﻞﺧﺪﺗﻰﺒﻄﻟﺍﻚﺟﻼﻋﻭﺍﺔﻴﻧﺎﻤﺴﺠﻟﺍﻚﺘﻟﺎﺣﻞﻫ 1 2 3 4
؟ﺔﻳﺩﺎﺼﺘﻗﺍﻞﻛﺎﺸﻣﻰﻟﺍﻯﺩﺍﻰﺒﻄﻟﺍﻚﺟﻼﻋﻭﺍﺔﻴﻧﺎﻤﺴﺠﻟﺍﻚﺘﻟﺎﺣﻞﻫ 1 2 3 4
:ﻙﻝﺓﻡﺉﺍﻝﻡﺭﺙﻙﺍﻝﺍ7-1ﻥﻱﺏﻡﻕﺭﻝﺍﻝﻭﺡﺓﺭﺉﺍﺩﺏﻯﺭﺵﺍ/ﺭﺵﺍﺀﺍﺝﺭﺓﻱﻝﺍﺕﻝﺍﺓﻝﺉﺱﺍﻝﺍﻯﻑ
؟ﻰﺿﺎﻤﻟﺍﻉﻮﺒﺳﻻﺍﻝﻼﺧﺎﻣﻮﻤﻋﻚﺘﺤﺻﻰﺟﺭﺪﺗ/ﺝﺭﺪﺗﻒﻴﻛ
1 2 3 4 5 6 7
ﺯﺎﺘﻤﻣﺍﺪﺟءﻰﺳ
؟ﻰﺿﺎﻤﻟﺍﻉﻮﺒﺳﻻﺍﻝﻼﺧﻚﺗﺎﻴﺣﺓﺩﻮﺟﻰﺟﺭﺪﺗ/ﺝﺭﺪﺗﻒﻴﻛ
1 2 3 4 5 6 7
ﺯﺎﺘﻤﻣﺍﺪﺟءﻰﺳ
.ﻲﺿﺎﻤﻟﺍﻉﻮﺒﺳﻷﺍﻝﻼﺧﻞﻛﺎﺸﻤﻟﺍﻭﺃﺽﺍﺮﻋﻷﺍﻩﺬﻫﻦﻣﺎﻬﻴﻓﺖﻴﻧﺎﻋﻲﺘﻟﺍﺔﺟﺭﺪﻟﺍﻰﻟﺇﺓﺭﺎﺷﻹﺍﻰﺟﺮﻳ.ﺔﻴﻟﺎﺘﻟﺍﺽﺍﺮﻋﻷﺎﺑﻢﻬﺘﺑﺎﺻﺇﻦﻋﻥﺎﻴﺣﻷﺍﺾﻌﺑﻲﻓﻰﺿﺮﻤﻟﺍﻎﻠﺒﻳ
ﻲﺿﺎﻤﻟﺍﻉﻮﺒﺳﻷﺍﻝﻼﺧ
ءﻰﺷﻻ ﻼﻴﻠﻗ ءﻰﺸﻟﺍﺾﻌﺑ ﺍﺪﺟﺍﺮﻴﺜﻛ
ﺎﻬﻴﻓﺖﻠﻌﺳﻲﺘﻟﺍﺕﺍﺮﻤﻟﺍﺩﺪﻋﻮﻫﺎﻣ 1 2 3 4
؟ﺎًﻣﺩﺖﻠﻌﺳﻞﻫ 1 2 3 4
؟ﺎﺤﻳﺮﺘﺴﻣﺖﻧﺃﻭﺲﻔﻨﺘﻟﺍﻲﻓﻖﻴﻀﺑﺕﺮﻌﺷﻞﻫ 1 2 3 4
؟ﻲﺸﻤﻟﺍﺪﻨﻋﺲﻔﻨﺘﻟﺍﻲﻓﻖﻴﻀﺑﺕﺮﻌﺷﻞﻫ 1 2 3 4
؟ﻢﻟﻼﺴﻟﺍﺩﻮﻌﺻﺀﺎﻨﺛﺃﺲﻔﻨﺘﻟﺍﻲﻓﻖﻴﻀﺑﺕﺮﻌﺷﻞﻫ 1 2 3 4
؟ﻥﺎﺴﻠﻟﺍﻭﺃﻢﻔﻟﺍﻲﻓﺏﺎﻬﺘﻟﺎﺑﺕﺮﻌﺷﻞﻫ 1 2 3 4
؟ﻊﻠﺒﻟﺍﻲﻓﺔﺑﻮﻌﺼﺑﺕﺮﻌﺷﻞﻫ 1 2 3 4
؟ﻦﻴﻣﺪﻘﻟﺍﻭﺃﻦﻳﺪﻴﻟﺍﻲﻓﻞﻴﻤﻨﺘﺑﺕﺮﻌﺷﻞﻫ 1 2 3 4
؟ﻙﺮﻌﺸﺑﻂﻗﺎﺴﺗﺙﻭﺪﺣﺖﻈﺣﻻﻞﻫ 1 2 3 4
؟ﺭﺪﺼﻟﺍﻲﻓﻢﻟﺄﺑﺕﺮﻌﺷﻞﻫ 1 2 3 4
؟ﻒﺘﻜﻟﺍﻭﺃﻉﺍﺭﺬﻟﺍﻲﻓﻢﻟﺄﺑﺕﺮﻌﺷﻞﻫ 1 2 3 4
ﻚﻤﺴﺟﻦﻣﻯﺮﺧﻷﺍﺀﺍﺰﺟﻷﺍﻲﻓﻢﻟﺄﺑﺕﺮﻌﺷﻞﻫ 1 2 3 4
...................ﻦﻳﺎﻓﺏﺎﺠﻳﻻﺎﺑﺩﺮﻟﺍﻥﺎﻛﺍﺫﺍ
؟ﻢﻟﻷﺍﺪﺿﺀﺍﻭﺩﻱﺃﺖﻟﻭﺎﻨﺗﻞﻫ
1ﻼﻛ2ﻢﻌﻧ
؟ﺀﺍﻭﺪﻟﺍﻊﻔﻧﻯﺪﻣﻮﻫﺎﻤﻓ،ﺏﺎﺠﻳﻹﺎﺑﺩﺮﻟﺍﻥﺎﻛﺍﺫﺇ 1 2 3 4
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Common terminology criteria for adverse events v3.0 (CTCAE)
(Appendix III) [9]
Cough
Grade 0 None
Grade 1 Mild, symptomatic, non-narcotic medications
only indicated
Grade 2 Moderate, symptomatic, requiring narcotic antitussive
Grade 3 Severe cough or coughing spasms, poorly controlled or
unresponsive to treatment, significantly interfering
with sleep or ADL
Hemoptysis
Grade 0 None
Grade 1 Mild without blood transfusion
Grade 2 Moderate without blood transfusion
Grade 3 Severe requiring transfusion
Grade 4 Catastrophic bleeding, requiring major non-elective
intervention
Chest pain (Non-cardiac)
Grade 0 None
Grade 1 Mild pain not interfering with function
Grade 2 Moderate pain: pain or analgesics interfering with
function, but not interfering with activities of daily living
Grade 3 Severe pain: pain or analgesics severely interfering with
activities of daily living
Grade 4 Disabling
Dyspnea
Grade 0 None
Grade 1 Dyspnea on exertion, but can walk 1 flight of stairs
without stopping
Grade 2 Dyspnea on exertion but unable to walk 1 flight
of stairs or 1 city block (0.1 km) without stopping
Grade 3 Dyspnea at normal level of activity (with ADL)
Grade 4 Dyspnea at rest or requiring ventilator support
Dysphagia
Grade 0 None
Grade 1 Symptomatic, able to eat regular diet
Grade 2 Symptomatic and altered eating/swallowing (e.g., altered
dietary habits, oral supplements);
IV fluids indicated <24 h
Grade 3 Symptomatic and severely altered eating/swallowing (e.g.,
inadequate oral caloric or fluid intake); IV fluids, tube
feedings, or TPN indicated P24 h
Grade 4 Life-threatening consequences (e.g., obstruction,
perforation)
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